Why carry out this study?

Comprehensive real-world data examining the treatment characteristics, resource use, effectiveness, and safety of ceftazidime–avibactam against multidrug-resistant (MDR) bacteria are needed.

This study was conducted to describe the patterns of use of ceftazidime–avibactam and to determine the effectiveness and safety of ceftazidime–avibactam in real-world clinical practice.

What was learned from the study?

Among patients who received ceftazidime–avibactam for at least 72 h in real-world clinical practice across the European and LATAM regions:

Infection sources were mainly intra-abdominal, urinary, respiratory, bloodstream infection, and other infections (approximately 20% each).

K. pneumoniae was the most common microorganism identified in the latest microbiological evaluation before the start of ceftazidime–avibactam (59.3%).

Treatment success was achieved in 77.3% of patients overall (88.3% among patients with urinary infection).

The in-hospital mortality rate was 23.1%.